Global X S&P 500 U.S. Mkt Ldr TOP 50 ETF | 8-K: FY2026 Q2 Revenue: USD 0
I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 0.
EPS: As of FY2026 Q2, the actual value is USD -2.94.
EBIT: As of FY2026 Q2, the actual value is USD -4.12 M.
Financial Performance (Three Months Ended June 30, 2026 vs. 2025)
Net Loss
Calidi Biotherapeutics, Inc. reported a net loss of - $4,160 thousand for the second quarter of 2026, compared to - $5,761 thousand for the same period in 2025. The net loss attributable to common stockholders was - $4.2 million for Q2 2026, versus - $5.7 million for Q2 2025.
Net Loss Per Share
Net loss per share was - $2.94 for the second quarter of 2026, compared to - $31.75 for the comparable period in 2025, after adjusting for a 1-for-16 reverse stock split completed in July 2026.
Operating Expenses
- Research and Development Expenses were $2,558 thousand for Q2 2026, which was unchanged from $2,593 thousand in Q2 2025.
- General and Administrative Expenses were $1,592 thousand for Q2 2026, a reduction of $1.5 million or 48% compared to $3,071 thousand in Q2 2025.
Financial Position (as of June 30, 2026 vs. December 31, 2025)
Cash and Restricted Cash
Calidi Biotherapeutics, Inc. had $4,071 thousand in cash and $0.2 million in restricted cash as of June 30, 2026. This compares to $5,600 thousand in cash and $0.2 million in restricted cash as of December 31, 2025.
Total Assets
Total assets were $7,204 thousand as of June 30, 2026, down from $8,857 thousand as of December 31, 2025.
Total Liabilities
Total liabilities amounted to $4,071 thousand as of June 30, 2026, decreasing from $5,098 thousand as of December 31, 2025.
Total Equity
Total equity was $3,133 thousand as of June 30, 2026, compared to $3,759 thousand as of December 31, 2025.
Business Developments and Operational Metrics
- Calidi Biotherapeutics, Inc. received positive pre-IND feedback from the U.S. FDA for CLD-401, agreeing on the development strategy for a first-in-human study.
- The company showcased the versatility of its RedTail platform at the 2026 ASCO Annual Meeting with new CLD-501 data and is advancing its EpCam-targeted in situ TCE program.
- The Board of Directors was strengthened with the addition of Corsee Sanders, Ph.D.
Outlook / Guidance
Calidi Biotherapeutics, Inc. anticipates its lead drug candidate, CLD-401, entering the clinic during the first quarter of 2027, with plans to dose the first patient in a phase 1 trial. The company intends to maintain a tight focus on expense management to ensure sufficient capital for advancing its pipeline.